[go: up one dir, main page]

EA201891005A1 - Комбинированная терапия рака - Google Patents

Комбинированная терапия рака

Info

Publication number
EA201891005A1
EA201891005A1 EA201891005A EA201891005A EA201891005A1 EA 201891005 A1 EA201891005 A1 EA 201891005A1 EA 201891005 A EA201891005 A EA 201891005A EA 201891005 A EA201891005 A EA 201891005A EA 201891005 A1 EA201891005 A1 EA 201891005A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
cancer therapy
patient
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
EA201891005A
Other languages
English (en)
Inventor
Ричард Пол Бекманн
Грегори Пол Донохо
Айми Карис Лин
Фолькер Вахек
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201891005A1 publication Critical patent/EA201891005A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Данное изобретение относится к способу лечения плоскоклеточных гистологических типов рака, рака молочной железы, рака предстательной железы, рака мочевого пузыря, рака шейки матки, рака эндометрия, рака яичников и колоректального рака у пациента, включающего введение пациенту, нуждающемуся в таком лечении, эффективного количества соединение формулыили его фармацевтически приемлемой соли в сочетании с эффективным количеством соединения формулыили его фармацевтически приемлемой соли.
EA201891005A 2015-12-15 2016-12-08 Комбинированная терапия рака EA201891005A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562267462P 2015-12-15 2015-12-15
PCT/US2016/065503 WO2017105982A1 (en) 2015-12-15 2016-12-08 Combination therapy for cancer

Publications (1)

Publication Number Publication Date
EA201891005A1 true EA201891005A1 (ru) 2018-12-28

Family

ID=57590897

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891005A EA201891005A1 (ru) 2015-12-15 2016-12-08 Комбинированная терапия рака

Country Status (15)

Country Link
US (1) US20180228795A1 (ru)
EP (1) EP3389660B1 (ru)
JP (1) JP6359197B2 (ru)
KR (1) KR20180081580A (ru)
CN (1) CN108472293A (ru)
AU (1) AU2016370297A1 (ru)
BR (1) BR112018011203A2 (ru)
CA (1) CA3005358A1 (ru)
EA (1) EA201891005A1 (ru)
HK (1) HK1254687A1 (ru)
IL (1) IL259097A (ru)
MX (1) MX2018007225A (ru)
NZ (1) NZ742470A (ru)
SG (1) SG11201803903YA (ru)
WO (1) WO2017105982A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8850801A1 (es) * 2008-12-17 2010-07-27 Lilly Co Eli Compuestos útiles para inhibir chk1
BR112013011918A2 (pt) * 2010-11-16 2020-08-25 Array Biopharma, Inc inibidor de chk1, composição farmacêutica e kit compreendendo o referido inibidor
JO3003B1 (ar) * 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
CA2860665A1 (en) * 2012-01-05 2013-07-11 Dana-Farber Cancer Institute, Inc. Methods of treating cancer

Also Published As

Publication number Publication date
IL259097A (en) 2018-06-28
MX2018007225A (es) 2018-08-01
EP3389660A1 (en) 2018-10-24
AU2016370297A1 (en) 2018-05-24
HK1254687A1 (zh) 2019-07-26
US20180228795A1 (en) 2018-08-16
EP3389660B1 (en) 2019-10-16
KR20180081580A (ko) 2018-07-16
NZ742470A (en) 2019-09-27
SG11201803903YA (en) 2018-06-28
BR112018011203A2 (pt) 2018-11-21
CA3005358A1 (en) 2017-06-22
JP6359197B2 (ja) 2018-07-18
JP2018502873A (ja) 2018-02-01
CN108472293A (zh) 2018-08-31
WO2017105982A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
EA201692472A1 (ru) Соединения для лечения рака мозга
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
MX394676B (es) Métodos para tratar el cáncer.
IL270511A (en) Combination therapies using niraparib and pembrolizumab for treating cancer
IL267795A (en) Combined treatment for cancer
JO3735B1 (ar) مركبات ألكين بها استبدال رباعي واستخداماتها
PH12017500493A1 (en) Combination therapy
EA201791736A1 (ru) Комбинированная терапия для лечения рака
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
EA201591925A1 (ru) Терапевтические композиции и их применение
MX388722B (es) Compuestos para tratar el cancer de ovario.
EA201692470A1 (ru) Фармацевтические комбинации
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
EA201792560A1 (ru) Наночастицы для применения в качестве терапевтической вакцины
SG11202103141YA (en) Combination therapy for the treatment of cancer
IL281439A (en) Combined treatment for blood cancer
IL279591A (en) Cancer treatment methods using combination therapy
EA201790604A1 (ru) Ингибиторы гистондеметилазы
SG11202105736QA (en) Combination therapy for the treatment of cancer
EP3849544A4 (en) POLYTHERAPY FOR THE TREATMENT OF PROSTATE CANCER
EA201892311A1 (ru) Производные 2-анилинопиримидина в качестве терапевтических агентов для лечения рака мозга